republic-os/legislation/us/states/ca/20192020/ab-922.md

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags

type	title	description	jurisdiction	legislature	session	identifier	citation	classification	subjects	status	primary_sponsors	version_count	action_count	vote_count	first_action	last_action	source	source_identifier	source_url	source_hash	vintage	source_snapshot	retrieved_at	confidence	tags
Bill	Reproductive health and research: oocyte procurement.	Existing law prohibits human oocytes or embryos from being acquired, sold, offered for sale, received, or otherwise transferred for valuable consideration for medical research or development of medical therapies, and prohibits payment in excess of the amount of reimbursement of direct expenses to be made to any research subject to encourage an individual to produce human oocytes for the purposes of medical research. Before obtaining informed consent from a subject for assisted oocyte production (AOP) or any alternative method of ovarian retrieval on a subject for the purpose of procuring oocytes for research or the development of medical therapies, existing law requires a physician and surgeon to provide to the subject a standardized medically accurate written summary of health and consumer issues associated with AOP, as specified. Existing law also requires all oocyte extractions for research to be approved by an institutional review board, as defined.	us/states/ca	California Legislature	20192020	AB 922	California AB 922 (20192020)	bill	Reproductive health and research: oocyte procurement.	enacted	Burke	6	19	5	2019-02-20	2019-10-13	openstates	ocd-bill/a8126183-368b-480e-92de-3689a189b216	http://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=201920200AB922	e89f36298c4cbff21c53a70fb15e0bd0a355085aa7de40905b2ffa7d92e5bb09	2026-07-01	https://data.openstates.org/daily/2026-07-01/public.pgdump	2026-07-06	reported	legislation bill us-ca

California AB 922 (20192020) — Reproductive health and research: oocyte procurement.

Existing law prohibits human oocytes or embryos from being acquired, sold, offered for sale, received, or otherwise transferred for valuable consideration for medical research or development of medical therapies, and prohibits payment in excess of the amount of reimbursement of direct expenses to be made to any research subject to encourage an individual to produce human oocytes for the purposes of medical research. Before obtaining informed consent from a subject for assisted oocyte production (AOP) or any alternative method of ovarian retrieval on a subject for the purpose of procuring oocytes for research or the development of medical therapies, existing law requires a physician and surgeon to provide to the subject a standardized medically accurate written summary of health and consumer issues associated with AOP, as specified. Existing law also requires all oocyte extractions for research to be approved by an institutional review board, as defined.

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

1. 02/20/19 - Introduced (filed) — source
2. 04/11/19 - Amended Assembly (committee substitute) — source
3. 09/06/19 - Amended Senate (committee substitute) — source
4. 10/13/19 - Chaptered (committee substitute) — source
5. AB922 (committee substitute) — source
6. 09/18/19 - Enrolled (enrolled) — source

Votes

• AB 922 Burke Concurrence in Senate Amendments — 74–0 (pass) · lower
• Do pass — 6–1 (pass) · upper
• AB 922 Burke Assembly Third Reading — 68–0 (pass) · lower
• Do pass as amended. — 14–0 (pass) · lower
• 3rd Reading AB922 Burke By Portantino — 28–4 (pass) · upper

Sponsors

• Burke — primary (person)

Timeline

The legislative action history — every referral, reading, and vote.

• 2019-02-20 Read first time. To print. reading-1
• 2019-02-21 From printer. May be heard in committee March 23.
• 2019-03-04 Referred to Com. on HEALTH. referral-committee
• 2019-04-10 From committee: Amend, and do pass as amended. (Ayes 14. Noes 0.) (April 9). amendment-passage, committee-passage, amendment-introduction
• 2019-04-11 Read second time and amended. Ordered returned to second reading. amendment-passage, reading-1, reading-2
• 2019-04-22 Read second time. Ordered to third reading. reading-1, reading-2
• 2019-05-20 Read third time. Passed. Ordered to the Senate. (Ayes 68. Noes 0. Page 1720.) passage, reading-3, reading-1
• 2019-05-20 In Senate. Read first time. To Com. on RLS. for assignment. reading-1
• 2019-05-29 Referred to Com. on HEALTH. referral-committee
• 2019-06-12 From committee: Do pass. (Ayes 6. Noes 1.) (June 12). committee-passage-favorable, committee-passage
• 2019-06-13 Read second time. Ordered to third reading. reading-1, reading-2
• 2019-09-06 Read third time and amended. Ordered to second reading. amendment-passage, reading-3, reading-1
• 2019-09-09 Read second time. Ordered to third reading. reading-1, reading-2
• 2019-09-11 Read third time. Passed. Ordered to the Assembly. (Ayes 28. Noes 4. Page 2857.). passage, reading-3, reading-1
• 2019-09-11 In Assembly. Concurrence in Senate amendments pending.
• 2019-09-12 Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 74. Noes 0. Page 3486.). amendment-passage, committee-passage-favorable
• 2019-09-25 Enrolled and presented to the Governor at 3:30 p.m.
• 2019-10-13 Approved by the Governor. executive-signature
• 2019-10-13 Chaptered by Secretary of State - Chapter 864, Statutes of 2019.

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/a8126183-368b-480e-92de-3689a189b216. Confidence: reported (aggregated from official California legislature records).